NCT03374488 2025-08-22Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaIncyte CorporationPhase 3 Completed84 enrolled 13 charts
NCT03260894 2025-07-29Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Incyte CorporationPhase 3 Completed129 enrolled 13 charts
NCT02178722 2022-02-14Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersIncyte CorporationPhase 1/2 Completed444 enrolled 19 charts
NCT03277352 2021-07-22INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Terminated10 enrolled 14 charts
NCT03361228 2020-05-21A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsIncyte CorporationPhase 1/2 Terminated5 enrolled 4 charts